Alliances
TCR targeting HA-1 antigen for hematological and solid tumors provides initial clinical safety and tolerability data
Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China.
During the annual congress of the French Society of Pathology which is held held from 5th to 8th November 2018 in Paris, AP-HP, Greater Paris University Hospitals and TRIBVN Healthcare are pleased to announce a 5-year strategic partnership to develop and operate a National Telepathology Platform.
When drug trials are mentioned, mental dots are connected to large hospitals first, with names like the Cleveland Clinic, the Mayo Clinic, or New York Presbyterian Hospital coming to mind. Often overlooked, however, are smaller regional hospitals, important players in the total research picture that are rarely acknowledged as contributors in the information game.
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab).
Viking Ninja joins growing roster of influential fitness and lifestyle influencers
Development, licence and supply agreement for treatment of migraine in US market
GE Healthcare partners with Wego to provide locally manufactured single-use consumables for bioprocessing in China
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products
PRESS RELEASES